Trial Profile
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination With Other Investigational Agents in Subjects With High Risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Favezelimab/pembrolizumab (Primary) ; Pembrolizumab (Primary) ; Vibostolimab+pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE 057
- Sponsors Merck Sharp & Dohme Corp.
- 27 Jan 2024 Results from cohort c, presented at the 2024 Genitourinary Cancers Symposium
- 01 May 2023 Results of exploratory analysis (As of May 25, 2022)assessing outcomes of patients in KEYNOTE-057 cohort A who underwent Radical Cystectomy after discontinuing Pembrolizumab presented at the 118th Annual Meeting of the American Urological Association
- 01 May 2023 Results is assessing efficacy and Cystectomy from Cohort B presented at the 118th Annual Meeting of the American Urological Association.